Literature DB >> 17952648

Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue.

Eiron Cudaback1, Nephi Stella.   

Abstract

The last quarter century has borne witness to great advances in both the detection and treatment of numerous cancers. Even so, malignancies of the central nervous system, especially high-grade astrocytomas, continue to thwart our best efforts toward effective chemotherapeutic strategies. With prognosis remaining bleak, the time for serious consideration of alternative therapies has arrived. Various preparations of the marijuana plant, Cannabis sativa, and related synthetic and endogenous compounds, may constitute just such an alternative. Cannabinoids, although much maligned historically for their psychotropic effects and clear abuse potential, have long been used medicinally and are now staging an impressive comeback, as recent studies have begun to explore their powerful anti-tumoral properties. In this study, we review in vitro and in vivo evidence supporting the use of cannabinoids for treatment of brain tumors. We further propose the continued intense investigation of cannabinoid efficacies as novel anti-cancer agents, especially in models recapitulating such properties within the unique environment of the brain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17952648     DOI: 10.1007/s12035-007-0016-z

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  89 in total

1.  Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment.

Authors:  J Priller; A Flügel; T Wehner; M Boentert; C A Haas; M Prinz; F Fernández-Klett; K Prass; I Bechmann; B A de Boer; M Frotscher; G W Kreutzberg; D A Persons; U Dirnagl
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

Review 2.  Origins of brain tumors--a disease of stem cells?

Authors:  Elena I Fomchenko; Eric C Holland
Journal:  Nat Clin Pract Neurol       Date:  2006-06

3.  Effects of delta9-tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture.

Authors:  A C White; J A Munson; A E Munson; R A Carchman
Journal:  J Natl Cancer Inst       Date:  1976-03       Impact factor: 13.506

4.  Marijuana research findings: 1980.

Authors: 
Journal:  NIDA Res Monogr       Date:  1980

5.  Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.

Authors:  Jonathan S Berman; Catherine Symonds; Rolfe Birch
Journal:  Pain       Date:  2004-12       Impact factor: 6.961

Review 6.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

7.  Brain monoglyceride lipase participating in endocannabinoid inactivation.

Authors:  T P Dinh; D Carpenter; F M Leslie; T F Freund; I Katona; S L Sensi; S Kathuria; D Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

8.  Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid.

Authors:  Christopher J Fowler; Kent-Olov Jonsson; Anna Andersson; Juha Juntunen; Tomi Järvinen; Séverine Vandevoorde; Didier M Lambert; Jeffrey C Jerman; Darren Smart
Journal:  Biochem Pharmacol       Date:  2003-09-01       Impact factor: 5.858

9.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice.

Authors:  E C Holland; W P Hively; R A DePinho; H E Varmus
Journal:  Genes Dev       Date:  1998-12-01       Impact factor: 11.361

10.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

View more
  1 in total

1.  The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas.

Authors:  Eiron Cudaback; William Marrs; Thomas Moeller; Nephi Stella
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.